Not planned for U.S. and UK Media Berlin, March 20, 2023– The Chinese National Medical Products Administration (NMPA) has actually authorized the oral androgen receptor inhibitor (ARi) Nubeqa ™ (darolutamide) in mix with docetaxel for the treatment of clients with metastatic hormone-sensitive prostate cancer (mHSPC). Nubeqa is currently authorized in China for the treatment of clients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high threat of establishing metastatic illness. “Prostate cancer cases in China have actually increased considerably over the last few years. Intensifying that, almost a 3rd of clients who are freshly detected will have metastatic illness. We are for that reason happy that clients in China will now have a brand-new treatment alternative for metastatic hormone-sensitive prostate cancer that postpones illness development, extends survival and keeps lifestyle”, stated Christine Roth, Member of the Executive Committee of Bayer’s Pharmaceuticals Division and Head of the Oncology SBU at Bayer. “Bayer is devoted to enhancing health results for individuals coping with prostate cancerand that as numerous qualified clients as possible gain access to Nubeqa.” The approval is based upon the favorable arise from the Phase III ARASENS trial, which showed that darolutamide plus androgen deprivation treatment (ADT) in mix with docetaxel considerably decreased the danger of death by 32.5% compared to ADT with docetaxel, in clients with metastatic hormone-sensitive prostate cancer (mHSPC). Furthermore, the darolutamide mix revealed constant advantages throughout scientifically pertinent secondary endpoints, with the general occurrence of treatment-emergent unfavorable occasions being comparable in between treatment arms. These outcomes were released in The New England Journal of Medicine.1 Darolutamide is being examined in a broad advancement program with 3 extra continuous or scheduled big medical research studies, to assess its possible throughout prostate cancer clients from early- to late-stage illness. This consists of the ARANOTE Phase III trial assessing darolutamide plus androgen deprivation treatment (ADT) versus ADT alone for mHSPC. Nubeqa has actually been established collectively by Bayer and Orion Corporation, an internationally running Finnish pharmaceutical business. About the ARASENS Trial The ARASENS trial is the only randomized, Phase III, multi-center, double-blind, trial which was prospectively developed to compare making use of a second-generation oral androgen receptor inhibitor (ARi), darolutamide, plus ADT in mix with docetaxel to ADT plus docetaxel (a standard suggested standard-of-care) in metastatic hormone-sensitive prostate cancer (mHSPC). An overall of 1,306 freshly identified clients were randomized in a 1:1 ratio to get 600 mg of darolutamide two times a day or matching placebo, plus ADT in mix with docetaxel. The main endpoint of this trial was general survival (OS). Secondary endpoints consisted of time to castration-resistant prostate cancer (CRPC), time to discomfort development, time to very first symptomatic skeletal occasion (SSE), time to initiation of subsequent anticancer treatment, all assessed at 12‐week periods, in addition to negative occasions (AEs) as a procedure of security and tolerability. Arise from this trial were released in the New England Journal of Medicine.1 A plain language summary publication of these information was released in Future Oncology.2 The ARASENS trial showed that darolutamide plus ADT in mix with docetaxel substantially decreased the threat of death by 32.5% compared to ADT with docetaxel alone.1 Improvements in the secondary endpoints supported the advantage observed in the main endpoint, total survival.1 About Metastatic Hormone-Sensitive Prostate Cancer Prostate cancer is the 2nd most typically detected malignancy in males worldwide. In 2020, an approximated 1.4 million guys were identified with prostate cancer, and about 375,000 passed away from the illness around the world.3 At the time of medical diagnosis, many guys have localized prostate cancer, suggesting their cancer is restricted to the prostate gland and can be treated with alleviative surgical treatment or radiotherapy. Upon regression, when the illness will metastasize or spread out, or if the illness is recently identified, however has actually currently spread out, the illness is hormone-sensitive and androgen deprivation treatment (ADT) is the foundation of treatment. Existing treatment alternatives for males with metastatic hormone-sensitive prostate cancer (mHSPC) consist of hormonal agent treatment, such as ADT, androgen receptor path inhibitors plus ADT or a mix of ADT and docetaxel. Regardless of these treatments, a big percentage of guys with mHSPC will ultimately experience development to metastatic castration-resistant prostate cancer (mCRPC), a condition with high morbidity and minimal survival. About Nubeqa ™ (darolutamide) Darolutamide is an oral androgen receptor inhibitor (ARi) with an unique chemical structure that binds to the receptor with high affinity and shows strong antagonistic activity, thus hindering the receptor function and the development of prostate cancer cells. The low capacity for blood-brain barrier penetration for darolutamide is supported by preclinical designs and neuroimaging information in healthy people. This is supported by the general low occurrence of main nerve system (CNS)-associated unfavorable occasions (AEs) compared to placebo as seen in the ARAMIS Phase III trial and the enhanced spoken knowing and memory observed in the darolutamide arm of the Phase II ODENZA trial.4 Nubeqa is authorized in more than 80 nations around the globe for the treatment of clients with non-metastatic castration-resistant prostate cancer (nmCRPC). It is likewise authorized for the treatment of clients with metastatic hormone-sensitive prostate cancer (mHSPC) in a variety of markets consisting of the U.S., Japan, EU and China. Filings in other areas are underway or prepared. Bayer thinks that the peak sales capacity for Nubeqa might surpass EUR3 billion. The substance is likewise being examined in additional research studies throughout numerous phases of prostate cancer, consisting of in the ARANOTE Phase III trial examining darolutamide plus androgen deprivation treatment (ADT) versus ADT alone for metastatic hormone-sensitive prostate cancer (mHSPC), in addition to the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) led worldwide Phase III co-operative group DASL-HiCaP (ANZUP1801) trial assessing darolutamide as an adjuvant treatment for localized prostate cancer with really high danger of reoccurrence. Info about these trials can be discovered at www.clinicaltrials.gov. In addition, a research study to check out the capacity of darolutamide in the early setting for clients who have actually experienced an increase in their prostate particular antigen (PSA) levels following surgical treatment or radiation, is likewise prepared. About Prostate Cancer at Bayer is devoted to providing science for a much better life by advancing a portfolio of ingenious treatments. The business has the enthusiasm and decision to establish brand-new medications that assist enhance and extend the lives of individuals dealing with cancer. Prostate cancer is the 2nd most typically identified cancer in men3 and a crucial location of focus for Bayer. The business’s franchise consists of 2 items on the marketplace (Nubeqa ™ and Xofigo ™) and a number of substances in advancement, consisting of a special method of advancing targeted alpha treatments. Bayer is concentrated on resolving the special requirements of prostate cancer clients, offering treatments that extend their lives throughout the various phases of the illness and permitting them to continue their daily activities, so that they can live longer, much better lives. About Bayer is a worldwide business with core proficiencies in the life science fields of healthcare and nutrition. Its services and products are developed to assist individuals and the world prosper by supporting efforts to master the significant obstacles provided by a growing and aging international population. Bayer is devoted to driving sustainable advancement and producing a favorable effect with its organizations. At the very same time, the Group intends to increase its making power and develop worth through development and development. The Bayer brand name means trust, dependability and quality throughout the world. In financial 2022, the Group used around 101,000 individuals and had sales of 50.7 billion euros. R&D costs prior to unique products totaled up to 6.2 billion euros. To learn more, go to www.bayer.com. Discover more info at https://pharma.bayer.com/ Follow us on Facebook: http://www.facebook.com/bayer Follow us on Twitter: @BayerPharma Forward-Looking Statements This release might include positive declarations based upon present presumptions and projections made by Bayer management. Numerous recognized and unidentified threats, unpredictabilities and other elements might result in product distinctions in between the real future outcomes, monetary scenario, advancement or efficiency of the business and the price quotes offered here. These aspects consist of those talked about in Bayer’s public reports which are offered on the Bayer site at www.bayer.com. The business presumes no liability whatsoever to upgrade these positive declarations or to adhere them to future occasions or advancements. Referral 1. Smith M, Hussain M., Saad F. et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022; 386:1132– 1142. https://www.nejm.org/doi/full/10.1056/NEJMoa2119115 2. Smith M., Hussain M., Saad F. et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a client and caretaker viewpoint and plain language summary of the ARASENS trial. Future Oncol. 2022; 18:21:2585 -2597. https://doi.org/10.2217/fon-2022-0433. http://dx.doi.org/10.15585/mmwr.mm6941a1 3. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21660. Accessed January 2023. 4. Colomba E. et al. ODENZA: A French potential, randomized, open-label, multicenter, cross-over stage II trial of choice in between darolutamide and enzalutamide in guys with asymptomatic or slightly symptomatic metastatic castrate-resistant prostate cancer (CRPC). J Clin Onc 2021; 39 (15_suppl): 5046-5046.